๎
๎ผ
๎
TG Therapeutics Inc
TGTX31.070USD
+0.340+1.11%
์ข
๊ฐย 12/24, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
4.82B์๊ฐ์ด์ก
10.15P/E TTM
๎
์์ธํ ๋ด์ฉ์ TG Therapeutics Inc ํ์ฌ
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonโs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ TGTX
ํ์ฌ ์ด๋ฆTG Therapeutics Inc
์์ฅ์ผDec 14, 1995
CEOWeiss (Michael S)
์ง์ ์338
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃDec 14
์ฃผ์3020 Carrington Mill Blvd., Suite 475
๋์MORRISVILLE
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ27560-5435
์ ํ18775758489
์น์ฌ์ดํธhttps://www.tgtherapeutics.com/
์ข
๋ชฉ ์ฝ๋ TGTX
์์ฅ์ผDec 14, 1995
CEOWeiss (Michael S)
TG Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
-18.15%
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.16M
-33.77%
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
600.61K
-19.72%
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
+5.56%
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
-2.19%
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
222.89K
+10.63%
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
+8.27%
์์ต ๋ถ์
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Oct 6
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Oct 6
FY2025Q1
FY2024
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Total product revenue, net
119.66M
99.01%
Royalty Revenue
605.00K
0.50%
Other Revenue
558.00K
0.46%
License Revenue
38.00K
0.03%
Milestone Revenue
0.00
0.00%
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
๊ธฐํ
64.59%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
BlackRock Institutional Trust Company, N.A.
11.86%
The Vanguard Group, Inc.
9.75%
Weiss (Michael S)
5.77%
State Street Investment Management (US)
5.10%
ClearBridge Investments, LLC
2.93%
๊ธฐํ
64.59%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
34.37%
Investment Advisor/Hedge Fund
17.35%
Hedge Fund
7.07%
Individual Investor
6.78%
Research Firm
3.06%
Pension Fund
1.30%
Bank and Trust
0.39%
Family Office
0.13%
Sovereign Wealth Fund
0.06%
๊ธฐํ
29.49%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
698
101.46M
63.91%
-17.24M
2025Q2
693
115.94M
73.03%
-21.56M
2025Q1
704
116.82M
73.80%
-25.76M
2024Q4
657
113.87M
72.65%
-36.14M
2024Q3
598
117.83M
76.11%
-20.28M
2024Q2
544
109.58M
70.90%
-28.91M
2024Q1
535
105.41M
68.45%
-29.01M
2023Q4
542
104.64M
69.13%
-36.73M
2023Q3
552
104.67M
69.33%
-30.54M
2023Q2
543
102.45M
68.58%
-35.33M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
BlackRock Institutional Trust Company, N.A.
19.13M
12.06%
-84.56K
-0.44%
Jun 30, 2025
The Vanguard Group, Inc.
15.77M
9.94%
+203.00K
+1.30%
Jun 30, 2025
Weiss (Michael S)
13.82M
8.71%
--
--
Apr 14, 2025
State Street Investment Management (US)
7.62M
4.8%
+184.34K
+2.48%
Jun 30, 2025
ClearBridge Investments, LLC
3.05M
1.92%
+408.10K
+15.43%
Jun 30, 2025
Soleus Capital Management, L.P.
2.24M
1.41%
-602.77K
-21.17%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.49M
2.2%
+207.89K
+6.33%
Jun 30, 2025
Pictet Asset Management Ltd.
1.91M
1.2%
-489.69K
-20.43%
Jun 30, 2025
Hood River Capital Management LLC
1.57M
0.99%
+11.02K
+0.71%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
Invesco S&P SmallCap Health Care ETF
2.89%
State Street SPDR S&P Biotech ETF
1.93%
Virtus LifeSci Biotech Products ETF
1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
1.44%
Invesco S&P SmallCap Momentum ETF
1.4%
Direxion Daily S&P Biotech Bull 3X Shares
1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
0.65%
First Trust NASDAQ Pharmaceuticals ETF
0.63%
Principal U.S. Small-Cap ETF
0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.61%
๋ ๋ณด๊ธฐ
Invesco S&P SmallCap Health Care ETF
๋น์จ2.89%
State Street SPDR S&P Biotech ETF
๋น์จ1.93%
Virtus LifeSci Biotech Products ETF
๋น์จ1.49%
Invesco S&P SmallCap 600 Pure Growth ETF
๋น์จ1.44%
Invesco S&P SmallCap Momentum ETF
๋น์จ1.4%
Direxion Daily S&P Biotech Bull 3X Shares
๋น์จ1.11%
State Street SPDR S&P 600 Small Cap Growth ETF
๋น์จ0.65%
First Trust NASDAQ Pharmaceuticals ETF
๋น์จ0.63%
Principal U.S. Small-Cap ETF
๋น์จ0.62%
Vanguard S&P Small-Cap 600 Growth Index Fund
๋น์จ0.61%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
TG Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎TG Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
BlackRock Institutional Trust Company, N.A.๋ 19.13M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.06%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 15.77M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.94%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Weiss (Michael S)๋ 13.82M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 8.71%๋ฅผ ์ฐจ์งํฉ๋๋ค.
State Street Investment Management (US)๋ 7.62M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 4.80%๋ฅผ ์ฐจ์งํฉ๋๋ค.
ClearBridge Investments, LLC๋ 3.05M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 1.92%๋ฅผ ์ฐจ์งํฉ๋๋ค.
BlackRock Institutional Trust Company, N.A.๋ 19.13M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.06%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 15.77M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 9.94%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Weiss (Michael S)๋ 13.82M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 8.71%๋ฅผ ์ฐจ์งํฉ๋๋ค.
State Street Investment Management (US)๋ 7.62M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 4.80%๋ฅผ ์ฐจ์งํฉ๋๋ค.
ClearBridge Investments, LLC๋ 3.05M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 1.92%๋ฅผ ์ฐจ์งํฉ๋๋ค.
TG Therapeutics Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎TG Therapeutics Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Weiss (Michael S)์ ๋๋ค.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Weiss (Michael S)์ ๋๋ค.
TG Therapeutics Inc(TGTX)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, TG Therapeutics Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 698๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 101.46M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 63.91%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น -9.12% ์ฆ๊ฐํ ์์น์
๋๋ค.
TG Therapeutics Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎FY2025Q1 ๊ธฐ์ค, TG Therapeutics Inc์ Total product revenue, net ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ 119.66M๋ก ์ ์ฒด ๋งค์ถ์ 99.01%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
